Drugs / Donor CD34+ and CD3+ cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03707262 | Nov 2019 → May 2027 expected | transplant rejection | Jeffrey Veale, MD | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Donor CD34+ and CD3+ cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03707262 ↗ |
| Route | Intravenous | “an intravenous infusion of granulocyte colony-stimulating factor (GCSF)-mobilized, Miltenyi-enriched CD34+ cells” NCT03707262 ↗ |